Treatment results and prognostic factors in primary thyroid lymphoma patients: a rare cancer network study.

Details

Ressource 1Download: serval:BIB_B64146B4B35F.P001 (199.12 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_B64146B4B35F
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Treatment results and prognostic factors in primary thyroid lymphoma patients: a rare cancer network study.
Journal
Annals of Oncology
Author(s)
Onal C., Li Y.X., Miller R.C., Poortmans P., Constantinou N., Weber D.C., Atasoy B.M., Igdem S., Ozsahin M., Ozyar E.
ISSN
1569-8041[electronic], 0923-7534[linking]
Publication state
Published
Issued date
2011
Volume
22
Number
1
Pages
156-164
Language
english
Abstract
Background: This study analyzed prognostic factors and treatment outcomes of primary thyroid lymphoma.
Patients and Methods: Data were retrospectively collected for 87 patients (53 stage I and 34 stage II) with median age 65 years. Fifty-two patients were treated with single modality (31 with chemotherapy alone and 21 with radiotherapy alone) and 35 with combined modality treatment. Median follow-up was 51 months.
Results: Sixty patients had aggressive lymphoma and 27 had indolent lymphoma. The 5- and 10-year overall survival (OS) rates were 74% and 71%, respectively, and the disease-free survival (DFS) rates were 68% and 64%. Univariate analysis revealed that age, tumor size, stage, lymph node involvement, B symptoms, and treatment modality were prognostic factors for OS, DFS, and local control (LC). Patients with thyroiditis had significantly better LC rates. In multivariate analysis, OS was influenced by age, B symptoms, lymph node involvement, and tumor size, whereas DFS and LC were influenced by B symptoms and tumor size. Compared with single modality treatment, patients treated with combined modality had better 5-year OS, DFS, and LC.
Conclusions: Combined modality leads to an excellent prognosis for patients with aggressive lymphoma but does not improve OS and LC in patients with indolent lymphoma.
Pubmed
Web of science
Open Access
Yes
Create date
08/03/2011 8:43
Last modification date
25/09/2019 6:10
Usage data